{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:36:10Z","timestamp":1791401770392,"version":"4.3.3"},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["CA009666"],"award-info":[{"award-number":["CA009666"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["C1100632"],"award-info":[{"award-number":["C1100632"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.humpath.2026.106179","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T15:24:59Z","timestamp":1780154699000},"page":"106179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The role of advanced molecular diagnostics in informing targeted therapies for AML"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9595-1279","authenticated-orcid":false,"given":"Jennifer","family":"Marvin-Peek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghayas C.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval G.","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2026.106179_bib1","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.humpath.2026.106179_bib2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41408-024-01143-2","article-title":"Current status and research directions in acute myeloid leukemia","volume":"14","author":"Kantarjian","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.humpath.2026.106179_bib3","volume":"2","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.humpath.2026.106179_bib4","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and Histiocytic\/Dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2026.106179_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26751","article-title":"The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms","volume":"98","author":"Thiele","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.humpath.2026.106179_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.27625","article-title":"Acute myeloid leukemia: 2025 update on diagnosis, Risk-Stratification, and management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.humpath.2026.106179_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2024.05.001","article-title":"SOHO State of the art updates and next Questions\u2014Who classification of Acute Myeloid leukemia","volume":"24","author":"Loghavi","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.humpath.2026.106179_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101156","article-title":"Practical considerations in clinical application of WHO 5th and ICC classification schemes for acute myeloid leukemia","volume":"64","author":"Chandra","year":"2024","journal-title":"Blood Rev"},{"key":"10.1016\/j.humpath.2026.106179_bib10","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib11","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ajh.27628","article-title":"Clinico-Genomic interrogation of secondary-type acute Myeloid leukemia: Response and outcomes to contemporary therapies","volume":"100","author":"Senapati","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.humpath.2026.106179_bib12","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib13","doi-asserted-by":"crossref","unstructured":"D\u00f6hner, H., Sierra Hospital Santa Creu Sant Pau, J. & Eytan Stein, S. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. https:\/\/doi.org\/10.1182\/blood.2024025409\/2239875\/blood.2024025409.pdf.","DOI":"10.1182\/blood.2024025409"},{"key":"10.1016\/j.humpath.2026.106179_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101196","article-title":"Cytogenetics in the genomic era","volume":"33","author":"Granada","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.humpath.2026.106179_bib15","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1586\/erm.10.85","article-title":"Molecular diagnosis of acute myeloid leukemia","volume":"10","author":"Watt","year":"2010","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.humpath.2026.106179_bib16","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021014309","article-title":"Guiding the global evolution of cytogenetic testing for hematologic malignancies","volume":"139","author":"Akkari","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/1097-0142(19920915)70:4+<1701::AID-CNCR2820701609>3.0.CO;2-S","article-title":"Cytogenetic analysis in the diagnosis of acute leukemia","volume":"70","author":"Heim","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2026.106179_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.70000","article-title":"Impact of cytogenetic response to therapy on long-term survival in acute Myeloid leukemia","volume":"100","author":"Hanna","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.humpath.2026.106179_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.12625","article-title":"Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia","volume":"164","author":"Medeiros","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humpath.2026.106179_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.12446","article-title":"Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia","volume":"94","author":"Lazarevic","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.humpath.2026.106179_bib21","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-023-02102-9","article-title":"Panel-based RNA fusion sequencing improves diagnostics of pediatric acute myeloid leukemia","volume":"38","author":"Hoffmeister","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2026.106179_bib23","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2017-03-734533","article-title":"The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice","volume":"130","author":"Kuo","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib24","article-title":"Molecular testing for acute myeloid leukemia","volume":"19","author":"Qin","year":"2022","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.humpath.2026.106179_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/nature07517","article-title":"Accurate whole human genome sequencing using reversible terminator chemistry","volume":"456","author":"Bentley","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2026.106179_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/nrg2626","article-title":"Sequencing technologies the next generation","volume":"11","author":"Metzker","year":"2010","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.humpath.2026.106179_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11030483","article-title":"Revealing the mysteries of Acute myeloid leukemia: from quantitative PCR through next-generation sequencing and systemic metabolomic profiling","volume":"11","author":"Panuzzo","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.humpath.2026.106179_bib28","article-title":"Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project","volume":"106","author":"Sargas","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2026.106179_bib29","doi-asserted-by":"crossref","DOI":"10.2353\/jmoldx.2009.080121","article-title":"A comparison of two methods for screening CEBPA mutations in patients with acute myeloid leukemia","volume":"11","author":"Ahn","year":"2009","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.humpath.2026.106179_bib30","doi-asserted-by":"crossref","DOI":"10.4081\/hr.2020.8957","article-title":"Advancing leukemia diagnostics: role of next generation sequencing (ngs) in acute myeloid leukemia","volume":"12","author":"Haferlach","year":"2020","journal-title":"Hematol Rep"},{"key":"10.1016\/j.humpath.2026.106179_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmoldx.2012.08.001","article-title":"Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data","volume":"15","author":"Spencer","year":"2013","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.humpath.2026.106179_bib32","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2018015925","article-title":"A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations","volume":"2","author":"Levis","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2026.106179_bib33","article-title":"Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia","author":"Al-Ali","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.humpath.2026.106179_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01078-8","article-title":"Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: an ALFA study","volume":"14","author":"Hirsch","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.humpath.2026.106179_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood-2020-140016","article-title":"Ultrasensitive measurable residual disease (MRD) detection in Acute Myeloid Leukemia (AML) using a targeted Next Generation Sequencing (NGS) Panel","volume":"136","author":"Duchstein","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib36","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1182\/blood-2025-3513","article-title":"A novel multi-target NGS application for molecular monitoring of measurable residual disease in Acute Myeloid Leukemia","volume":"146","author":"Condorelli","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00718-1","article-title":"Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS\/AML patients","volume":"12","author":"Balducci","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.humpath.2026.106179_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmoldx.2022.09.009","article-title":"Clinical validation and diagnostic utility of optical genome mapping for enhanced cytogenomic analysis of hematological neoplasms","volume":"24","author":"Sahajpal","year":"2022","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.humpath.2026.106179_bib39","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2022007583","article-title":"Optical genome mapping in acute myeloid leukemia: a multicenter evaluation","volume":"7","author":"Levy","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2026.106179_bib40","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/ajh.27435","article-title":"Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia","volume":"99","author":"Loghavi","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.humpath.2026.106179_bib41","doi-asserted-by":"crossref","first-page":"9236","DOI":"10.1073\/pnas.96.16.9236","article-title":"Digital PCR","volume":"96","author":"Vogelstein","year":"1999","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.humpath.2026.106179_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093141","article-title":"Digital pcr: a reliable tool for analyzing and monitoring hematologic malignancies","volume":"21","author":"Coccaro","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.humpath.2026.106179_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20092249","article-title":"Digital PCR in myeloid malignancies: ready to replace quantitative PCR?","volume":"20","author":"Cilloni","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.humpath.2026.106179_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmoldx.2017.01.004","article-title":"Droplet digital PCR is a reliable tool for monitoring minimal residual disease in acute promyelocytic leukemia","volume":"19","author":"Brunetti","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.humpath.2026.106179_bib45","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2020.1755855","article-title":"Subclonal patterns in follow-up of acute myeloid leukemia combining whole exome sequencing and ultrasensitive IBSAFE digital droplet analysis","volume":"61","author":"Pettersson","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.humpath.2026.106179_bib46","doi-asserted-by":"crossref","DOI":"10.1111\/ped.15859","article-title":"Monitoring measurable residual disease in NUP98::NSD1-positive acute myeloid leukemia","volume":"67","author":"Okuchi","year":"2025","journal-title":"Pediatr Int"},{"key":"10.1016\/j.humpath.2026.106179_bib47","doi-asserted-by":"crossref","DOI":"10.1172\/JCI91964","article-title":"Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse","volume":"127","author":"Parkin","year":"2017","journal-title":"J Clin Investig"},{"key":"10.1016\/j.humpath.2026.106179_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2018.04.013","article-title":"Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia","volume":"69","author":"Tan","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.humpath.2026.106179_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.14151","article-title":"Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning","volume":"112","author":"Gronlund","year":"2024","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.humpath.2026.106179_bib50","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2024534","article-title":"Genome sequencing as an alternative to cytogenetic analysis in Myeloid cancers","volume":"384","author":"Duncavage","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2026.106179_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-025-02774-5","article-title":"Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment","volume":"39","author":"Voss","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2026.106179_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.1263","article-title":"1203P analytical evaluation of whole genome sequencing for acute myeloid leukemia","volume":"35","author":"Malagoli Tagliazucchi","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2026.106179_bib53","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminhematol.2025.06.002","article-title":"AML diagnostics in the 21st century: use of AI","volume":"62","author":"Haferlach","year":"2025","journal-title":"Semin Hematol"},{"key":"10.1016\/j.humpath.2026.106179_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmoldx.2025.09.001","article-title":"Evaluation of long-read genome sequencing for genomic profiling of Myeloid cancers","volume":"27","author":"Abel","year":"2025","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.humpath.2026.106179_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-022-01796-7","article-title":"Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children","volume":"37","author":"Stratmann","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2026.106179_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.clnves.2025.100007","article-title":"Multi-omics advances for molecular characterization, precision medicine, and prognostic implications in leukemia","volume":"1","author":"Hou","year":"2025","journal-title":"Cell Investigation"},{"key":"10.1016\/j.humpath.2026.106179_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/nm.4125","article-title":"Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia","volume":"22","author":"Li","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.humpath.2026.106179_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2022.07.002","article-title":"Integrative analysis of drug response and clinical outcome in acute myeloid leukemia","volume":"40","author":"Bottomly","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.humpath.2026.106179_bib59","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024027244","article-title":"Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes","volume":"145","author":"Reville","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib60","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood.2025030689","article-title":"Advancing the classification of hematolymphoid neoplasms together: for patients, medicine, and science","volume":"147","author":"Hasserjian","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib61","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.31331","article-title":"Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels","volume":"124","author":"DiNardo","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2026.106179_bib63","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2025.287794","article-title":"Serial next-generation sequencing for detecting germline predisposition in acute myeloid leukemia","author":"Ahn","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2026.106179_bib64","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2025.288448","article-title":"Beyond somatic mutations: the role of next generation sequencing in identifying germline predisposition in patients with acute myeloid leukemia","author":"Loghavi","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2026.106179_bib65","doi-asserted-by":"crossref","DOI":"10.1007\/s11899-022-00684-2","article-title":"Approach toward germline predisposition syndromes in patients with hematologic malignancies","volume":"17","author":"Atluri","year":"2022","journal-title":"Current Hematologic Malignancy Reports"},{"key":"10.1016\/j.humpath.2026.106179_bib66","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2026.106179_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humpath.2026.106179_bib75","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for Acute Myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2026.106179_bib80","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3 -Mutated AML","volume":"386","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2026.106179_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humpath.2026.106179_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.humpath.2026.106179_bib91","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1 -Mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2026.106179_bib93","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1 -Mutated acute Myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2026.106179_bib92","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2022009411","article-title":"Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML","volume":"7","author":"de Botton","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2026.106179_bib90","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib107","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A -Rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2026.106179_bib108","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1200\/JCO-25-01694","article-title":"Ziftomenib in relapsed or refractory NPM1-Mutated AML","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2026.106179_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35662","article-title":"Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia","volume":"131","author":"Jen","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2026.106179_bib68","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V86.3.862.862","article-title":"Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML\/RAR-\u03b1 protein","volume":"86","author":"Dyck","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib69","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00503-6","article-title":"Core binding factor acute myelogenous leukemia-2021 treatment algorithm","volume":"11","author":"Borthakur","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.humpath.2026.106179_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.23927","article-title":"Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival","volume":"113","author":"Borthakur","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2026.106179_bib72","doi-asserted-by":"crossref","DOI":"10.4081\/oncol.2012.e8","article-title":"An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment","volume":"6","author":"Grafone","year":"2012","journal-title":"Oncol Rev"},{"key":"10.1016\/j.humpath.2026.106179_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.humpath.2026.106179_bib74","article-title":"Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis","volume":"33","author":"He","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2026.106179_bib76","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-021-01179-4","article-title":"Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603\/RATIFY trial","volume":"35","author":"Larson","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2026.106179_bib77","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/blood-2024-201058","article-title":"10 year Follow-up of CALGB 10603\/Ratify: midostaurin versus placebo plus intensive chemotherapy in newly diagnosed FLT3 mutant acute Myeloid leukemia patients aged 18-60 years","volume":"144","author":"Stone","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib81","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3 -Mutated AML","author":"Short","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2026.106179_bib82","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1182\/blood-2025-654","article-title":"Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): interim results from the phase 1\/2 VICEROY study","volume":"146","author":"Altman","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib83","series-title":"30th Congress of the European Hematology Association (EHA 2025)","article-title":"Phase I\/II Study of decitabine, venetoclax, and quizartinib triplet combination in FLT3-ITD mutated AML","author":"Yilmaz","year":"2025"},{"key":"10.1016\/j.humpath.2026.106179_bib84","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.27236","article-title":"Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups","volume":"99","author":"Bataller","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.humpath.2026.106179_bib85","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2026.106179_bib86","doi-asserted-by":"crossref","DOI":"10.1309\/AJCPD7NR2RMNQDVF","article-title":"Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features","volume":"135","author":"Patel","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2026.106179_bib87","doi-asserted-by":"crossref","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2026.106179_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.humpath.2026.106179_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting \u03b1-Ketoglutarate to 2-Hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.humpath.2026.106179_bib94","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.7012","article-title":"Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine","volume":"41","author":"De Botton","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2026.106179_bib95","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00640","article-title":"Outcomes of frontline triplet regimens with a hypomethylating agent, venetoclax, and isocitrate dehydrogenase inhibitor for intensive chemotherapy-ineligible patients with isocitrate dehydrogenase-mutated AML","author":"Dinardo","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2026.106179_bib96","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-208771","article-title":"Phase 1b\/2 Study of decitabine and venetoclax in combination with the targeted mutant IDH1 inhibitor olutasidenib for patients with relapsed\/refractory AML, high risk MDS, or newly diagnosed AML not eligible for chemotherapy with an IDH1 mutation","volume":"144","author":"DiNardo","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib97","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1182\/blood-2025-5192","article-title":"Phase 3 study of ivosidenib (IVO) and azacitidine (AZA) with or without venetoclax in adult patients with newly diagnosed IDH1-mutated AML or MDS\/AML ineligible for intensive chemotherapy (EVOLVE-1)","volume":"146","author":"D\u00f6hner","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib98","doi-asserted-by":"crossref","DOI":"10.1038\/sj.leu.2404808","article-title":"Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias","volume":"21","author":"Mullighan","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2026.106179_bib99","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.21.1.224-234.2001","article-title":"Defining roles for HOX and MEIS1 genes in induction of Acute Myeloid leukemia","volume":"21","author":"Thorsteinsdottir","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.humpath.2026.106179_bib100","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2026.106179_bib101","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in Acute Myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2026.106179_bib102","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00557-6","article-title":"Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements","volume":"11","author":"Issa","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.humpath.2026.106179_bib103","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-025-02848-4","article-title":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners","author":"Chonabayashi","year":"2026","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2026.106179_bib104","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023021359","article-title":"Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors","volume":"143","author":"Barajas","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib105","doi-asserted-by":"crossref","DOI":"10.1158\/2643-3230.BCD-25-0112","article-title":"Tandem duplications in UBTF create XPO1-Dependent nuclear export signals that reveal a leukemic therapeutic dependency","volume":"7","author":"Barajas","year":"2026","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.humpath.2026.106179_bib106","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-023-01906-z","article-title":"UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia","volume":"37","author":"Duployez","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2026.106179_bib109","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-204375","article-title":"Phase I\/II study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in R\/R AML","volume":"144","author":"Issa","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2025-47","article-title":"Phase II study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML","volume":"146","author":"Jen","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib111","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO-25-00914","article-title":"Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-Mutated or KMT2A-Rearranged AML","volume":"43","author":"Zeidner","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2026.106179_bib112","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1182\/blood-2025-3425","article-title":"Phase 1 study of revumenib in combination with intensive chemotherapy (IC) in patients (Pts) with newly diagnosed (ND) Acute Myeloid Leukemia (AML) harboring genetic alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708","volume":"146","author":"Aldoss","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib113","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood-2024-198218","article-title":"Ziftomenib combined with intensive induction (7+3) in newly diagnosed NPM1-m or KMT2A-r acute myeloid leukemia: interim phase 1a results from KOMET-007","volume":"144","author":"Zeidan","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib114","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1182\/blood-2025-5199","article-title":"Bleximenib in combination with intensive chemotherapy: a phase 1b study in newly diagnosed acute myeloid leukemia with KMT2A or NPM1 alterations","volume":"146","author":"D\u00f6hner","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib115","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020005037","article-title":"Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition","volume":"136","author":"Dzama","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib116","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01186-5","article-title":"What have we learned about TP53-mutated acute myeloid leukemia?","volume":"14","author":"Shahzad","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.humpath.2026.106179_bib117","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.70171","article-title":"MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia","volume":"207","author":"Jen","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humpath.2026.106179_bib118","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.541.541","volume":"110","author":"Grimwade","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib119","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2012-11-468348","article-title":"MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial","volume":"121","author":"Zhu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib120","article-title":"Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial","volume":"120","author":"Liu Yin","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib121","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2026.106179_bib122","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2022-159467","article-title":"Molecular MRD assessment is strongly prognostic in patients with NPM1 mutated AML receiving venetoclax based non-intensive therapy","volume":"140","author":"Othman","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib123","article-title":"2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD working party","author":"Cloos","year":"2025","journal-title":"Blood Journal"},{"key":"10.1016\/j.humpath.2026.106179_bib124","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023023096","article-title":"Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib125","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25514","article-title":"Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse","volume":"94","author":"Press","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.humpath.2026.106179_bib126","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024013758","article-title":"Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin","volume":"8","author":"R\u00fccker","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2026.106179_bib127","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2026.106179_bib128","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD\u2013mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2026.106179_bib129","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2024.0985","article-title":"Measurable residual FLT3 internal tandem duplication before allogeneic transplant for Acute Myeloid leukemia","volume":"10","author":"Dillon","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.humpath.2026.106179_bib130","article-title":"QUANTUM-FIRST: efficacy in newly diagnosed patients with fms-like tyrosine kinase 3-INTERNAL tandem duplication\u2013positive (FLT3-ITD+) acute myeloid leukemia (AML) WHO received continuation therapy","author":"Sekeres","year":"2024","journal-title":"European Hematology Association (EHA) Congress"},{"key":"10.1016\/j.humpath.2026.106179_bib131","doi-asserted-by":"crossref","DOI":"10.1158\/2643-3230.BCD-22-0205","article-title":"A phase Ib\/II study of ivosidenib with venetoclax \u00b1 azacitidine in IDH1-Mutated Myeloid malignancies","volume":"4","author":"Lachowiez","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.humpath.2026.106179_bib132","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1182\/bloodadvances.2025016726","article-title":"Utility of IDH1\/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia","volume":"9","author":"Boertjes","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2026.106179_bib133","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41409-023-02189-9","article-title":"Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide","volume":"59","author":"Ravindra","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.humpath.2026.106179_bib134","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817726001486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817726001486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:10:08Z","timestamp":1783159808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817726001486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":134,"alternative-id":["S0046817726001486"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2026.106179","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of advanced molecular diagnostics in informing targeted therapies for AML","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2026.106179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106179"}}